| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.24 | 3e-05 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.13 | 5e-05 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0001 |